Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

There's The Bolus! ANDA Sponsors Race To Avoid User Fee Spike

Executive Summary

In a year defined by application surges, more than 200 ANDAs were submitted in September, the last month of fiscal year 2017, likely to avoid paying a much higher application fee instituted Oct. 1.

You may also be interested in...



Complex ANDAs: Early Meetings With FDA Can Generate Bonus Communication

By conducting a product development or pre-submission meeting, sponsors can receive a mid-review cycle meeting for a complex product ANDA.

Generic User Fee Hikes Could Disrupt US FDA Drug Pricing Campaign

New GDUFA program fee is high enough that sponsors may withdraw applications to reduce their fee exposure, agency estimates.

ANDA Approvals Break Record, May Set New Normal

FDA's June approval total is highest of GDUFA era, but does it signal a new elevated productivity level for the generics program?

Related Content

Topics

UsernamePublicRestriction

Register

GB002031

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel